Skip to main content
PMC home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1994 Sep 2;126(6):1341–1351. doi: 10.1083/jcb.126.6.1341

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events

PMCID: PMC2290951  PMID: 8089169

Abstract

ICRF-193, a novel noncleavable, complex-stabilizing type topoisomerase (topo) II inhibitor, has been shown to target topo II in mammalian cells (Ishida, R., T. Miki, T. Narita, R. Yui, S. Sato, K. R. Utsumi, K. Tanabe, and T. Andoh. 1991. Cancer Res. 51:4909-4916). With the aim of elucidating the roles of topo II in mammalian cells, we examined the effects of ICRF-193 on the transition through the S phase, when the genome is replicated, and through the M phase, when the replicated genome is condensed and segregated. Replication of the genome did not appear to be affected by the drug because the scheduled synthesis of DNA and activation of cdc2 kinase followed by increase in mitotic index occurred normally, while VP-16, a cleavable, complex-stabilizing type topo II inhibitor, inhibited all these processes. In the M phase, however, late stages of chromosome condensation and segregation were clearly blocked by ICRF-193. Inhibition at the stage of compaction of 300-nm diameter chromatin fibers to 600-nm diameter chromatids was demonstrated using the drug during premature chromosome condensation (PCC) induced in tsBN2 baby hamster kidney cells in early S and G2 phases. In spite of interference with M phase chromosome dynamics, other mitotic events such as activation of cdc2 kinase, spindle apparatus reorganization and disassembly and reassembly of nuclear envelopes occurred, and the cells traversed an unusual M phase termed "absence of chromosome segregation" (ACS)-M phase. Cells then continued through further cell cycle rounds, becoming polyploid and losing viability. This effect of ICRF-193 on the cell cycle was shown to parallel that of inactivation of topo II on the cell cycle of the ts top2 mutant yeast. The results strongly suggest that the essential roles of topo II are confined to the M phase, when the enzyme decatenates intertwined replicated chromosomes. In other phases of the cycle, including the S phase, topo II may thus play a complementary role with topo I in controlling the torsional strain accumulated in various genetic processes.

Full Text

The Full Text of this article is available as a PDF (2.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi Y., Luke M., Laemmli U. K. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell. 1991 Jan 11;64(1):137–148. doi: 10.1016/0092-8674(91)90215-k. [DOI] [PubMed] [Google Scholar]
  2. Andoh T., Sato M., Narita T., Ishida R. Role of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotechnol Appl Biochem. 1993 Oct;18(Pt 2):165–174. [PubMed] [Google Scholar]
  3. Berrios M., Osheroff N., Fisher P. A. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4142–4146. doi: 10.1073/pnas.82.12.4142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchenau P., Saumweber H., Arndt-Jovin D. J. Consequences of topoisomerase II inhibition in early embryogenesis of Drosophila revealed by in vivo confocal laser scanning microscopy. J Cell Sci. 1993 Apr;104(Pt 4):1175–1185. doi: 10.1242/jcs.104.4.1175. [DOI] [PubMed] [Google Scholar]
  5. Cai J. C., Shu H. L., Tang C. F., Komatsu T., Matsuno T., Narita T., Yaguchi S., Koide Y., Takase M. Synthesis and antitumor properties of N1-acyloxymethyl derivatives of bis(2,6-dioxopiperazines). Chem Pharm Bull (Tokyo) 1989 Nov;37(11):2976–2983. doi: 10.1248/cpb.37.2976. [DOI] [PubMed] [Google Scholar]
  6. Chen M., Beck W. T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 1993 Dec 15;53(24):5946–5953. [PubMed] [Google Scholar]
  7. Clarke D. J., Johnson R. T., Downes C. S. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci. 1993 Jun;105(Pt 2):563–569. doi: 10.1242/jcs.105.2.563. [DOI] [PubMed] [Google Scholar]
  8. D'Arpa P., Liu L. F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989 Dec 17;989(2):163–177. doi: 10.1016/0304-419x(89)90041-3. [DOI] [PubMed] [Google Scholar]
  9. DiNardo S., Voelkel K., Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A. 1984 May;81(9):2616–2620. doi: 10.1073/pnas.81.9.2616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Downes C. S., Mullinger A. M., Johnson R. T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8895–8899. doi: 10.1073/pnas.88.20.8895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Earnshaw W. C., Halligan B., Cooke C. A., Heck M. M., Liu L. F. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol. 1985 May;100(5):1706–1715. doi: 10.1083/jcb.100.5.1706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Earnshaw W. C., Heck M. M. Localization of topoisomerase II in mitotic chromosomes. J Cell Biol. 1985 May;100(5):1716–1725. doi: 10.1083/jcb.100.5.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Earnshaw W. C. Mitotic chromosome structure. Bioessays. 1988 Nov;9(5):147–150. doi: 10.1002/bies.950090502. [DOI] [PubMed] [Google Scholar]
  14. Ebina T., Otsuki K., Seto M., Ishida N. Specific G2 block in HeLa-S3 cells by neocarzinostatin. Eur J Cancer. 1975 Mar;11(3):155–158. doi: 10.1016/0014-2964(75)90110-3. [DOI] [PubMed] [Google Scholar]
  15. Enoch T., Nurse P. Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. Cell. 1990 Feb 23;60(4):665–673. doi: 10.1016/0092-8674(90)90669-6. [DOI] [PubMed] [Google Scholar]
  16. Gasser S. M., Laroche T., Falquet J., Boy de la Tour E., Laemmli U. K. Metaphase chromosome structure. Involvement of topoisomerase II. J Mol Biol. 1986 Apr 20;188(4):613–629. doi: 10.1016/s0022-2836(86)80010-9. [DOI] [PubMed] [Google Scholar]
  17. Hartwell L. H., Weinert T. A. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989 Nov 3;246(4930):629–634. doi: 10.1126/science.2683079. [DOI] [PubMed] [Google Scholar]
  18. Hashimoto Y., Oshima H., Yuki H. Metaphase-arresting action of carcinostatic tenuazonic acid. Gan. 1972 Feb;63(1):79–85. [PubMed] [Google Scholar]
  19. Hellmann K., Newton K. A., Whitmore D. N., Hanham I. W., Bond J. V. Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma. Br Med J. 1969 Mar 29;1(5647):822–824. doi: 10.1136/bmj.1.5647.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hirano T., Mitchison T. J. Cell cycle control of higher-order chromatin assembly around naked DNA in vitro. J Cell Biol. 1991 Dec;115(6):1479–1489. doi: 10.1083/jcb.115.6.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hirano T., Mitchison T. J. Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts. J Cell Biol. 1993 Feb;120(3):601–612. doi: 10.1083/jcb.120.3.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Holm C., Goto T., Wang J. C., Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 1985 Jun;41(2):553–563. doi: 10.1016/s0092-8674(85)80028-3. [DOI] [PubMed] [Google Scholar]
  23. Horwitz S. B., Horwitz M. S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973 Nov;33(11):2834–2836. [PubMed] [Google Scholar]
  24. Ishida R., Miki T., Narita T., Yui R., Sato M., Utsumi K. R., Tanabe K., Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991 Sep 15;51(18):4909–4916. [PubMed] [Google Scholar]
  25. Ishida R., Takahashi T., Nishimoto T. Chromosomes of G2 arrested cells are easily analyzed by use of the 'tsBN2' mutation. Cell Struct Funct. 1985 Dec;10(4):417–420. doi: 10.1247/csf.10.417. [DOI] [PubMed] [Google Scholar]
  26. Ishimi Y., Ishida R., Andoh T. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro. Mol Cell Biol. 1992 Sep;12(9):4007–4014. doi: 10.1128/mcb.12.9.4007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Krishan A., Paika K., Frei E., 3rd Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol. 1975 Sep;66(3):521–530. doi: 10.1083/jcb.66.3.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kung A. L., Sherwood S. W., Schimke R. T. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9553–9557. doi: 10.1073/pnas.87.24.9553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Li L. H., Fraser T. J., Olin E. J., Bhuyan B. K. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972 Dec;32(12):2643–2650. [PubMed] [Google Scholar]
  30. Lock R. B. Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res. 1992 Apr 1;52(7):1817–1822. [PubMed] [Google Scholar]
  31. Lock R. B., Ross W. E. Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res. 1990 Jun 15;50(12):3761–3766. [PubMed] [Google Scholar]
  32. Morla A. O., Draetta G., Beach D., Wang J. Y. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell. 1989 Jul 14;58(1):193–203. doi: 10.1016/0092-8674(89)90415-7. [DOI] [PubMed] [Google Scholar]
  33. Narita T., Koide Y., Yaguchi S., Kimura S., Izumisawa Y., Takase M., Inaba M., Tsukagoshi S. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother Pharmacol. 1991;28(4):235–240. doi: 10.1007/BF00685528. [DOI] [PubMed] [Google Scholar]
  34. Narita T., Yaguchi S., Komatsu T., Takase M., Hoshino A., Inaba M., Tsukagoshi S. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother Pharmacol. 1990;26(3):193–197. doi: 10.1007/BF02897198. [DOI] [PubMed] [Google Scholar]
  35. Newport J., Spann T. Disassembly of the nucleus in mitotic extracts: membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes. Cell. 1987 Jan 30;48(2):219–230. doi: 10.1016/0092-8674(87)90425-9. [DOI] [PubMed] [Google Scholar]
  36. Nishimoto T., Eilen E., Basilico C. Premature of chromosome condensation in a ts DNA- mutant of BHK cells. Cell. 1978 Oct;15(2):475–483. doi: 10.1016/0092-8674(78)90017-x. [DOI] [PubMed] [Google Scholar]
  37. Nishimoto T., Ishida R., Ajiro K., Yamamoto S., Takahashi T. The synthesis of protein(s) for chromosome condensation may be regulated by a post-transcriptional mechanism. J Cell Physiol. 1981 Nov;109(2):299–308. doi: 10.1002/jcp.1041090213. [DOI] [PubMed] [Google Scholar]
  38. Nishitani H., Ohtsubo M., Yamashita K., Iida H., Pines J., Yasudo H., Shibata Y., Hunter T., Nishimoto T. Loss of RCC1, a nuclear DNA-binding protein, uncouples the completion of DNA replication from the activation of cdc2 protein kinase and mitosis. EMBO J. 1991 Jun;10(6):1555–1564. doi: 10.1002/j.1460-2075.1991.tb07675.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 1990 Apr 5;344(6266):503–508. doi: 10.1038/344503a0. [DOI] [PubMed] [Google Scholar]
  40. Roberge M., Th'ng J., Hamaguchi J., Bradbury E. M. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells. J Cell Biol. 1990 Nov;111(5 Pt 1):1753–1762. doi: 10.1083/jcb.111.5.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Roca J., Ishida R., Berger J. M., Andoh T., Wang J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1781–1785. doi: 10.1073/pnas.91.5.1781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Roca J., Wang J. C. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell. 1992 Nov 27;71(5):833–840. doi: 10.1016/0092-8674(92)90558-t. [DOI] [PubMed] [Google Scholar]
  43. Shamu C. E., Murray A. W. Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase. J Cell Biol. 1992 Jun;117(5):921–934. doi: 10.1083/jcb.117.5.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]
  45. Smythe C., Newport J. W. Coupling of mitosis to the completion of S phase in Xenopus occurs via modulation of the tyrosine kinase that phosphorylates p34cdc2. Cell. 1992 Feb 21;68(4):787–797. doi: 10.1016/0092-8674(92)90153-4. [DOI] [PubMed] [Google Scholar]
  46. Steinmann K. E., Belinsky G. S., Lee D., Schlegel R. Chemically induced premature mitosis: differential response in rodent and human cells and the relationship to cyclin B synthesis and p34cdc2/cyclin B complex formation. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6843–6847. doi: 10.1073/pnas.88.15.6843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sumner A. T. Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis. J Cell Sci. 1992 Sep;103(Pt 1):105–115. doi: 10.1242/jcs.103.1.105. [DOI] [PubMed] [Google Scholar]
  48. TERASIMA T., TOLMACH L. J. Growth and nucleic acid synthesis in synchronously dividing populations of HeLa cells. Exp Cell Res. 1963 Apr;30:344–362. doi: 10.1016/0014-4827(63)90306-9. [DOI] [PubMed] [Google Scholar]
  49. Tanabe K., Ikegami Y., Ishida R., Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 1991 Sep 15;51(18):4903–4908. [PubMed] [Google Scholar]
  50. Tobey R. A. Different drugs arrest cells at a number of distinct stages in G2. Nature. 1975 Mar 20;254(5497):245–247. doi: 10.1038/254245a0. [DOI] [PubMed] [Google Scholar]
  51. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987 Sep 11;50(6):917–925. doi: 10.1016/0092-8674(87)90518-6. [DOI] [PubMed] [Google Scholar]
  52. Uemura T., Tanagida M. Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis. EMBO J. 1986 May;5(5):1003–1010. doi: 10.1002/j.1460-2075.1986.tb04315.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Uemura T., Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J. 1984 Aug;3(8):1737–1744. doi: 10.1002/j.1460-2075.1984.tb02040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Usui T., Yoshida M., Abe K., Osada H., Isono K., Beppu T. Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J Cell Biol. 1991 Dec;115(5):1275–1282. doi: 10.1083/jcb.115.5.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Vosberg H. P. DNA topoisomerases: enzymes that control DNA conformation. Curr Top Microbiol Immunol. 1985;114:19–102. doi: 10.1007/978-3-642-70227-3_2. [DOI] [PubMed] [Google Scholar]
  56. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  57. Wang J. C. Recent studies of DNA topoisomerases. Biochim Biophys Acta. 1987 Jun 6;909(1):1–9. doi: 10.1016/0167-4781(87)90040-6. [DOI] [PubMed] [Google Scholar]
  58. Wood E. R., Earnshaw W. C. Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II. J Cell Biol. 1990 Dec;111(6 Pt 2):2839–2850. doi: 10.1083/jcb.111.6.2839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wright S. J., Schatten G. Teniposide, a topoisomerase II inhibitor, prevents chromosome condensation and separation but not decondensation in fertilized surf clam (Spisula solidissima) oocytes. Dev Biol. 1990 Nov;142(1):224–232. doi: 10.1016/0012-1606(90)90166-g. [DOI] [PubMed] [Google Scholar]
  60. Yasuda H., Kamijo M., Honda R., Nagahara M., Ohba Y. The difference in murine CDC2 kinase activity between cytoplasmic and nuclear fractions during the cell cycle. Biochem Biophys Res Commun. 1990 Oct 30;172(2):371–376. doi: 10.1016/0006-291x(90)90682-d. [DOI] [PubMed] [Google Scholar]
  61. Yoshida M., Beppu T. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Exp Cell Res. 1988 Jul;177(1):122–131. doi: 10.1016/0014-4827(88)90030-4. [DOI] [PubMed] [Google Scholar]
  62. Zucker R. M., Elstein K. H. A new action for topoisomerase inhibitors. Chem Biol Interact. 1991;79(1):31–40. doi: 10.1016/0009-2797(91)90050-h. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES